EAM Global Investors’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

EAM Global Investors’s Portfolio CNCE Stock Details CNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-337,095	Closed	-$2.26M	–	256
2022 Q3	$2.26M	Sell	337,095 -51,635	-13%	-$313K	0.6%	52
2022 Q2	$1.64M	Buy	+388,730	New	+$1.54M	0.4%	119
2018 Q1	–	Sell	-39,327	Closed	-$1.02M	–	180
2017 Q4	$1.02M	Buy	+39,327	New	+$792K	0.52%	86

Other funds holding CNCE

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

EAM Global Investors's CNCE Position: Q4 2022 in Review

EAM Global Investors sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q4 2022, closing a stake of 337,095 shares — an estimated $2.26M sold.

EAM Global Investors first reported a position in CNCE in Q4 2017 and held it in 3 quarters. The position peaked at $2.26M in Q3 2022. 85 funds tracked by Wall St. Rank hold CNCE as of Q4 2022.

EAM Global Investors reported no remaining Concert Pharmaceuticals, Inc. position as of Q4 2022 after selling out during the quarter.
EAM Global Investors sold 337,095 Concert Pharmaceuticals, Inc. shares in Q4 2022, an estimated $2.26M.
EAM Global Investors first reported a position in Concert Pharmaceuticals, Inc. in Q4 2017 and held it in 3 quarters.
EAM Global Investors's Concert Pharmaceuticals, Inc. position peaked at $2.26M in Q3 2022.
85 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q4 2022.

Based on EAM Global Investors's 13F filing for Q4 2022, filed 14 Feb 2023.